Callan Family Office LLC Takes $896,000 Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Callan Family Office LLC acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 37,038 shares of the company's stock, valued at approximately $896,000.

A number of other hedge funds have also modified their holdings of HIMS. Crewe Advisors LLC acquired a new position in shares of Hims & Hers Health during the 4th quarter valued at $28,000. Raleigh Capital Management Inc. lifted its holdings in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares in the last quarter. US Bancorp DE lifted its holdings in Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after buying an additional 1,508 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new position in Hims & Hers Health in the 4th quarter worth $48,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Down 6.9 %

NYSE HIMS traded down $2.47 on Monday, hitting $33.48. The stock had a trading volume of 22,056,990 shares, compared to its average volume of 13,221,550. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98. The stock has a market cap of $7.44 billion, a price-to-earnings ratio of 76.48 and a beta of 1.37. The company's 50-day moving average is $37.64 and its two-hundred day moving average is $27.60.

Remove Ads

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to analysts' expectations of $494.56 million. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on HIMS. TD Cowen reiterated a "buy" rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Citigroup reiterated a "sell" rating and issued a $27.00 price objective on shares of Hims & Hers Health in a report on Thursday. Morgan Stanley lowered shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and boosted their price objective for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Needham & Company LLC boosted their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a report on Tuesday, February 25th. Finally, Piper Sandler boosted their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $37.23.

Insider Transactions at Hims & Hers Health

In other news, CEO Andrew Dudum sold 78,127 shares of the company's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $29.62, for a total value of $2,314,121.74. Following the completion of the sale, the chief executive officer now directly owns 109,956 shares of the company's stock, valued at approximately $3,256,896.72. This represents a 41.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 268,932 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now directly owns 169,803 shares of the company's stock, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,062,011 shares of company stock valued at $36,892,724. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.